The Treatment - A guide for life sciences companies coming to Europe
October 2016
On 3 October 2016, Taylor Wessing’s International Life Sciences Group launched The Treatment – A guide for life sciences companies coming to Europe. This unique publication is designed to provide a high level overview of the most important issues that should be considered for any life sciences company wishing to do business in Europe. It represents a distillation of our International Life Sciences Group's many years of experience in helping life sciences companies to do business in Europe and to thrive there.
Find out more and download your copy of The Treatment.
Your local contacts
- Simon Cohen, Partner - London
- Evelyne Friedel, Partner - Paris
- Dr. Manja Epping, Partner - Munich
- Wim Maas, Partner - Eindhoven
- Dr. Wolfgang Rehmann, Partner - Munich
- Dr. Dieter Natlacen
If you have any questions on this article or would like to propose a subject to be addressed by Synapse please contact us.
Latest topical issues
Advocate General Sharpston consider notified bodies may be liable to patients using medical devices
Three exclusivity to watch during Brexit
Calculation of SPC term in EU accession countries
Infringement of Swiss-form claims - the final word?
Previous articles
Medicines and medical devices regulation post-Brexit
The Medical Devices Regulation is coming!
European Council approves Trade Secrets Directive
Threats to sue for patent infringement - the risks
Attention returns to decisions on UPC opt-out
Life Sciences Issues in Corporate Transactions - Part 1
Life Sciences Issues in Corporate Transactions - Part 2
A go-to guide to the Unified Patent Court and Unitary Patent